Literature DB >> 9276743

Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

L I Brasoveanu1, E Fonsatti, A Visintin, M Pavlovic, I Cattarossi, F Colizzi, A Gasparollo, S Coral, V Horejsi, M Altomonte, M Maio.   

Abstract

Protectin (CD59), a glycosylphosphatidylinositol-anchored cell membrane glycoprotein, is differentially expressed on melanocytic cells and represents the main restriction factor of C-mediated lysis of melanoma cells. In this study, we report that CD59-positive melanoma cells constitutively release a soluble form of CD59 (sCD59), and that its levels directly correlate (r = 0.926; P < 0.05) with the amount of membrane-bound CD59. SDS-PAGE analysis showed that the molecular components of sCD59 are similar to those of cellular CD59 expressed by melanoma cells. Melanoma-released sCD59 is anchor positive since it inserts into cell membranes of homologous cells that transiently increase their expression of CD59. Moreover, sCD59 is functional: it blocks the binding of the anti-CD59 mAb YTH53.1 to melanoma cells and reverses its effects on C-mediated lysis. In fact, preincubation of mAb YTH53.1 with scalar doses of conditioned media of CD59-positive but not of CD59-negative melanoma cells reduced significantly (P < 0.05), and in a dose-dependent fashion, the enhancement of C-mediated lysis of anti-GD3-sensitized melanoma cells induced by the masking of cellular CD59 by mAb YTH53.1. Altogether, these data demonstrate that CD59-positive human melanoma cells release a soluble form of CD59 that is structurally similar to cellular CD59, retains its anchoring ability, is functional, and may impair the effectiveness of clinical approaches to humoral immunotherapy for human melanoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276743      PMCID: PMC508302          DOI: 10.1172/JCI119638

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma.

Authors:  M Altomonte; F Colizzi; G Esposito; M Maio
Journal:  N Engl J Med       Date:  1992-09-24       Impact factor: 91.245

2.  Melanoma immunotherapy: new dreams or solid hopes?

Authors:  M Maio; G Parmiani
Journal:  Immunol Today       Date:  1996-09

3.  Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues.

Authors:  S Meri; H Waldmann; P J Lachmann
Journal:  Lab Invest       Date:  1991-11       Impact factor: 5.662

Review 4.  Phosphatidylinositol-glycan linked proteins of the erythrocyte membrane.

Authors:  M J Telen; W F Rosse
Journal:  Baillieres Clin Haematol       Date:  1991-12

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol.

Authors:  I Stefanová; I Hilgert; H Kristofová; R Brown; M G Low; V Horejsí
Journal:  Mol Immunol       Date:  1989-02       Impact factor: 4.407

7.  Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.

Authors:  M Maio; M Altomonte; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

8.  Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential.

Authors:  M Maio; B Gulwani; J A Langer; R S Kerbel; G J Duigou; P B Fisher; S Ferrone
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

9.  Ganglioside GD3 shedding by human malignant melanoma cells.

Authors:  H Bernhard; K H Meyer zum Büschenfelde; W G Dippold
Journal:  Int J Cancer       Date:  1989-07-15       Impact factor: 7.396

10.  CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.

Authors:  A Davies; D L Simmons; G Hale; R A Harrison; H Tighe; P J Lachmann; H Waldmann
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  9 in total

1.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

2.  Expression of complement regulating factors in gastric cancer cells.

Authors:  T Inoue; M Yamakawa; T Takahashi
Journal:  Mol Pathol       Date:  2002-06

3.  Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.

Authors:  Timothy M Shaver; Brian D Lehmann; J Scott Beeler; Chung-I Li; Zhu Li; Hailing Jin; Thomas P Stricker; Yu Shyr; Jennifer A Pietenpol
Journal:  Cancer Res       Date:  2016-05-26       Impact factor: 12.701

Review 4.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

5.  Soluble CD59 in peritoneal dialysis: a potential biomarker for peritoneal membrane function.

Authors:  Bernardo Faria; Mariana Gaya da Costa; Carla Lima; Loek Willems; Ricardo Brandwijk; Stefan P Berger; Mohamed R Daha; Manuel Pestana; Marc A Seelen; Felix Poppelaars
Journal:  J Nephrol       Date:  2020-12-11       Impact factor: 3.902

6.  Microvesicles/exosomes as potential novel biomarkers of metabolic diseases.

Authors:  Günter Müller
Journal:  Diabetes Metab Syndr Obes       Date:  2012-08-07       Impact factor: 3.168

7.  Immune Protection of Retroviral Vectors Upon Molecular Painting with the Complement Regulatory Protein CD59.

Authors:  Susanne Heider; Sandra Kleinberger; Feliks Kochan; John A Dangerfield; Christoph Metzner
Journal:  Mol Biotechnol       Date:  2016-07       Impact factor: 2.695

Review 8.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

9.  Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Authors:  Ester Fonsatti; Anna Maria Di Giacomo; Michele Maio
Journal:  J Transl Med       Date:  2004-06-25       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.